Molecular and genetic basis of childhood cancer

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 211-234

  Rushton, Jennifer ^a   López Terrada, Dolores ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; Childhood; developmental pathways; embryonal tumors; epigenetics; genetic; molecular; molecular diagnostics; pathology; profiling; prognosis; risk stratification; tumor markers

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANTINEOPLASTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIN DEPENDENT KINASE 4; NEUROTROPHIN RECEPTOR; RAPAMYCIN; SURVIVIN; TRANSCRIPTION FACTOR PAX3;

ALGORITHM; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GROWTH; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHILDHOOD CANCER; CHROMOSOME 11Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COMPETITIVE INHIBITION; CYTOGENETICS; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DEVELOPMENTAL DISORDER; EMBRYO DEVELOPMENT; EPIGENETICS; EWING SARCOMA; FETUS DEVELOPMENT; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GANGLIONEUROMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOME ANALYSIS; GERM CELL TUMOR; HEPATOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; INHERITANCE; KIDNEY CARCINOMA; LIPOSARCOMA; MALIGNANT TRANSFORMATION; METASTASIS; MOLECULAR GENETICS; MYOBLAST; NEPHROBLASTOMA; NEUROBLASTOMA; ONCOGENE; ORGANOGENESIS; OSTEOSARCOMA; PATIENT MONITORING; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; PROTEIN TARGETING; RETINOBLASTOMA; RHABDOID TUMOR; RHABDOMYOSARCOMA; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CHILD; CHILD, PRESCHOOL; HUMANS; NEOPLASMS;

EID: 82955193251     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0199     Document Type: Article

References (273)

1. L. A. G. Ries, Cancer Statistics Review 1975-2002, National Cancer Institute Bethesda, 2005.
2. J. M. Maris and C. T. Denny, Focus on embryonal malignancies, Cancer Cell 2 (2002), 447-450.
3. A. T. Kho, Q. Zhao, Z. Cai, A. J. Butte, J. Y. Kim, S. L. Pomeroy et al. , Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers, Genes Dev 18 (2004), 629-640.
4. B. Dekel, Profiling gene expression in kidney development, Nephron Exp Nephrol 95 (2003), e1-6.
5. R. D. Palmer, N. L. Barbosa-Morais, E. L. Gooding, B. Muralidhar, C. M. Thornton, M. R. Pett et al. , Pediatric malignant germ cell tumors show characteristic transcriptome profiles, Cancer Res 68 (2008), 4239-4247.
6. D. Trochet, F. Bourdeaut, I. Janoueix-Lerosey, A. Deville, L. de Pontual, G. Schleiermacher et al. , Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma, Am J Hum Genet 74 (2004), 761-764.
7. D. G. Gilliland and M. S. Tallman, Focus on acute leukemias, Cancer Cell 1 (2002), 417-420.
8. A. G. Knudson, H. W. Jr. , Hethcote andB. W. Brown, Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma, Proc Natl Acad Sci U S A 72 (1975), 5116-5120.
9. T. J. H. Triche and P. H. B. Sorensen, Diagnostic Pathology of Pediatric Malignancies, in: Principles and Practice of Pediatric Oncology, P. A. Pizzo and D. G. Poplack, eds, Philadelphia: Lippincott Williams and Wilkins, 2006, pp. 185-235.
10. J. S. Dome andM. J. Coppes, Recent advances inWilms tumor genetics, Curr Opin Pediatr 14 (2002), 5-11.
11. R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein et al. , Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary, Clin Cancer Res 9 (2003), 5442-5453.
12. S. Hu-Lieskovan, J. Zhang, L. Wu, H. Shimada, D. E. Schofield and T. J. Triche, EWS-FLI1 fusion protein upregulates critical genes in neural crest development and isresponsible for the observed phenotype of Ewing's family of tumors, Cancer Res 65 (2005), 4633-4644.
13. T. K. Man, M. Chintagumpala, J. Visvanathan, J. Shen, L. Perlaky, J. Hicks et al. , Expression profiles of osteosarcoma that can predict response to chemotherapy, Cancer Res 65 (2005), 8142-8150.
14. G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock et al. , Molecular characterization of the pediatric preclinical testing panel, Clin Cancer Res 14 (2008), 4572-4583.
15. G. M. Brodeur and J. M. Maris, Neuroblastoma, in: Principles and Practice of Pediatric Oncology, P. A. Pizzo, D. G. Poplack, eds, Philadelphia: Lippincott Williams and Wilkins, 2006, pp. 905-932.
16. R. C. Seeger, G. M. Brodeur, H. Sather, A. Dalton, S. E. Siegel, K. Y. Wong et al. , Association of multiple copies of the Nmyc oncogene with rapid progression of neuroblastomas, N Engl J Med 313 (1985), 1111-1116.
17. N. Bown, S. Cotterill, M. Lastowska, S. O'Neill, A. D. Pearson, D. Plantaz et al. , Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma, N Engl J Med 340 (1999), 1954-1961.
18. N. Van Roy, G. Laureys, M. Van Gele, G. Opdenakker, R. Miura, P. van der Drift et al. , Analysis of 1;17 translocation breakpoints in neuroblastoma: implications for mapping of neuroblastoma genes, Eur J Cancer 33 (1997), 1974-1978.
19. A. Islam, H. Kageyama, N. Takada, T. Kawamoto, H. Takayasu, E. Isogai et al. , High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma, Oncogene 19 (2000), 617-623.
20. M. B. Godfried, M. Veenstra, P. v Sluis, K. Boon, R. v Asperen, M. C. Hermus et al. , The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23- H1 and nm23-H2, Oncogene 21 (2002), 2097-2101.
21. A. T. Look, F. A. Hayes, J. J. Shuster, E. C. Douglass, R. P. Castleberry, L. C. Bowman et al. , Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study, J Clin Oncol 9 (1991), 581-591.
22. E. F. Attiyeh, W. B. London, Y. P. Mosse, Q. Wang, C. Winter, D. Khazi et al. , Chromosome 1p and 11q deletions and outcome in neuroblastoma, N Engl J Med 353 (2005), 2243-2253.
23. J. Spicak, S. Vitko, M. Ryska, P. Trunecka, F. Belina, M. Krawczyk et al. , Liver transplantation in Eastern Europe, Liver Transpl 6 (2000), 665-669.
24. P. S. White, P. M. Thompson, T. Gotoh, E. R. Okawa, J. Igarashi, M. Kok et al. , Definition and characterization of a region of 1p36. 3 consistently deleted in neuroblastoma, Oncogene 24 (2005), 2684-2694.
25. A. Nakagawara, M. Arima-Nakagawara, N. J. Scavarda, C. G. Azar, A. B. Cantor and G. M. Brodeur, Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma, N Engl JMed 328 (1993), 847-854.
26. A. Nakagawara, C. G. Azar, N. J. Scavarda and G. M. Brodeur, Expression and function of TRK-B and BDNF in human neuroblastomas, Mol Cell Biol 14 (1994), 759-767.
27. Y. P. Mosse,M. Laudenslager, L. Longo, K. A. Cole, A. Wood, E. F. Attiyeh et al. , Identification of ALK as a major familial neuroblastoma predisposition gene, Nature 455 (2008), 930-935.
28. I. Janoueix-Lerosey, D. Lequin, L. Brugieres, A. Ribeiro, L. de Pontual, V. Combaret et al. , Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature 455 (2008), 967-970.
29. Y. Chen, J. Takita, Y. L. Choi, M. Kato, M. Ohira, M. Sanada et al. , Oncogenic mutations of ALK kinase in neuroblastoma, Nature 455 (2008), 971-974.
30. R. E. George, T. Sanda, M. Hanna, S. Frohling, W. ,2nd. Luther, J. Zhang et al. , Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature 455 (2008),975-978.
31. J. M. Maris, M. J. Weiss, Y. Mosse, G. Hii, C. Guo, P. S. White et al. , Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13, Cancer Res 62 (2002), 6651-6658.
32. L. H. J. M. Wexler, W. H. Helman, L. J. Rhabdomyosarcomas and Undifferentiated Sarcomas, in: Principles and Practice of Pediatric Oncology, D. G. Pizzo PaP, ed. , Philadelphia: Lippincott Williams and Wilkins, 2006, pp. 185-235.
33. P. Dias, B. Chen, B. Dilday, H. Palmer, H. Hosoi, S. Singh et al. , Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass, Am J Pathol 156 (2000), 399-408.
34. D. M. Parham, Pathologic classification of rhabdomyosarcomas and correlations with molecular studies, Mod Pathol 14 (2001), 506-514.
35. S. J. Qualman, C. M. Coffin, W. A. Newton, H. Hojo, T. J. Triche, D. M. Parham et al. , Intergroup Rhabdomyosarcoma Study: update for pathologists, Pediatr Dev Pathol 1 (1998), 550-561.
36. S. J. Qualman and R. A. Morotti, Risk assignment in pediatric soft-tissue sarcomas: an evolving molecular classification, Curr Oncol Rep 4 (2002), 123-130.
37. C. Turc-Carel, S. Lizard-Nacol, E. Justrabo, M. Favrot, T. Philip and E. Tabone, Consistent chromosomal translocation in alveolar rhabdomyosarcoma, Cancer Genet Cytogenet 19 (1986), 361-362.
38. M. Valentine, E. C. Douglass and A. T. Look, Closely linked loci on the long arm of chromosome 13 flank a specific 2;13 translocation breakpoint in childhood rhabdomyosarcoma, Cytogenet Cell Genet 52 (1989), 128-132.
39. F. G. Barr, N. Galili, J. Holick, J. A. Biegel, G. Rovera and B. S. Emanuel, Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma, Nat Genet 3 (1993), 113-117.
40. N. Galili, R. J. Davis, W. J. Fredericks, S. Mukhopadhyay, F. J. 3rd. Rauscher, B. S. Emanuel et al. , Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma, Nat Genet 5 (1993), 230-235.
41. J. A. Biegel, R. S. Meek, A. H. Parmiter, K. Conard and B. S. Emanuel, Chromosomal translocation t(1;13)(p36;q14) in a case of rhabdomyosarcoma, Genes Chromosomes Cancer 3 (1991), 483-484.
42. R. J. Davis, C. M. D'Cruz, M. A. Lovell, J. A. Biegel and F. G. Barr, Fusion of PAX7 to FKHR by the variant t(1;13) (p36;q14) translocation in alveolar rhabdomyosarcoma, Cancer Res 54 (1994), 2869-2872.
43. M. Wachtel, M. Dettling, E. Koscielniak, S. Stegmaier, J. Treuner, K. Simon-Klingenstein et al. , Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1, Cancer Res 64 (2004), 5539-5545.
44. J. A. Bridge, J. Liu, S. J. Qualman, R. Suijkerbuijk, G. Wenger, J. Zhang et al. , Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma,whereas amplification predominates in embryonal with anaplasia and alveolar subtypes, Genes Chromosomes Cancer 33 (2002), 310-321.
45. H. Scrable, D. Witte, H. Shimada, T. Seemayer, W. W. Sheng, S. Soukup et al. , Molecular differential pathology of rhabdomyosarcoma, Genes Chromosomes Cancer 1 (1989), 23-35.
46. J. A. Bridge and A. A. Sandberg, Cytogenetic and molecular genetic techniques as adjunctive approaches in the diagnosis of bone and soft tissue tumors, Skeletal Radiol 29 (2000), 249-258.
47. R. T. Kurmasheva, C. A. Peterson, D. M. Parham, B. Chen, R. E. McDonald and C. A. Cooney, Upstream CpG island methylation of the PAX3 gene in human rhabdomyosarcomas, Pediatr Blood Cancer 44 (2005), 328-337.
48. J. Khan,M. L. Bittner, L. H. Saal, U. Teichmann, D. O. Azorsa, G. C. Gooden et al. , cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene, Proc NatlAcad SciUSA 96 (1999), 13264-13269.
49. J. L. Bennicelli, R. H. Edwards and F. G. Barr, Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma, Proc Natl Acad Sci U S A 93 (1996), 5455-5459.
50. P. R. Bois, K. Izeradjene, P. J. Houghton, J. L. Cleveland, J. A. Houghton and G. C. Grosveldz, FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma, J Cell Biol 177 (2007), 563.
51. S. Bortoluzzi, A. Bisognin, C. Romualdi and G. A. Danieli, Novel genes, possibly relevant for molecular diagnosis or therapy of human rhabdomyosarcoma, detected by genomic expression profiling, Gene 348 (2005), 65-71.
52. M. Crescenzi, T. P. Fleming, A. B. Lassar, H. Weintraub and S. A. Aaronson, MyoD induces growth arrest independent of differentiation in normal and transformed cells, Proc Natl Acad Sci U S A 87 (1990), 8442-8446.
53. V. Sorrentino, R. Pepperkok, R. L. Davis, W. Ansorge and L. Philipson, Cell proliferation inhibited by MyoD1 independently of myogenic differentiation, Nature 345 (1990), 813-815.
54. L. M. Mulligan, G. J. Matlashewski, H. J. Scrable and W. K. Cavenee, Mechanisms of p53 loss in human sarcomas, Proc Natl Acad Sci U S A 87 (1990), 5863-5867.
55. Y. Hachitanda, S. Toyoshima, K. Akazawa and M. Tsuneyoshi, N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: its correlation with histologic features, Mod Pathol 11 (1998), 1222-1227.
56. D. Driman, P. S. Thorner, M. L. Greenberg, S. Chilton- MacNeill and J. Squire, MYCN gene amplification in rhabdomyosarcoma, Cancer 73 (1994), 2231-2237.
57. A. Iolascon, M. F. Faienza, B. Coppola, A. Rosolen, G. Basso, F. Della Ragione et al. , Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A,CDKN2B, andCDKN2C) in childhood rhabdomyosarcoma, Genes Chromosomes Cancer 15 (1996), 217-222.
58. D. Williamson, Y. J. Lu, T. Gordon, R. Sciot, A. Kelsey, C. Fisher et al. , Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype, J Clin Oncol 23 (2005), 880-888.
59. I. Hostein, M. Andraud-Fregeville, L. Guillou, M. J. Terrier- Lacombe, C. Deminiere, D. Ranchere et al. , Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens, Cancer 101 (2004), 2817-2824.
60. A. Heerema-McKenney, L. C. Wijnaendts, J. F. Pulliam, D. Lopez-Terrada, J. K. McKenney, S. Zhu et al. , Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype, Am J Surg Pathol 32 (2008), 1513-1522.
61. P. H. Sorensen, J. C. Lynch, S. J. Qualman, R. Tirabosco, J. F. Lim, H. M. Maurer et al. , PAX3-FKHR and PAX7- FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group, J Clin Oncol 20 (2002), 2672-2679.
62. F. G. Barr, S. J. Qualman, M. H. Macris, N. Melnyk, E. R. Lawlor, D. M. Strzelecki et al. , Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions, Cancer Res 62 (2002), 4704-4710.
63. F. G. Barr, J. Chatten, C. M. D'Cruz, A. E. Wilson, L. E. Nauta, L. M. Nycum et al. , Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas, Jama 273 (1995), 553-557.
64. J. A. Biegel, L. M. Nycum, V. Valentine, F. G. Barr and D. N. Shapiro, Detection of the t(2;13)(q35;q14) and PAX3-FKHR fusion in alveolar rhabdomyosarcoma by fluorescence in situ hybridization, Genes Chromosomes Cancer 12 (1995), 186-192.
65. U. H. Athale, S. A. Shurtleff, J. J. Jenkins, C. A. Poquette, M. Tan, J. R. Downing et al. , Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor, J Pediatr Hematol Oncol 23 (2001), 99-104.
66. M. P. G. Link, M. C. Meyers and P. A. Osteosarcoma, in: Principles and Practice of Pediatric Oncology, D. G. Pizzo PaP, ed. , Philadelphia: Lippincott Williams and Wilkins, 2006, pp. 1074-1115.
67. J. A. Biegel, R. B. Womer and B. S. Emanuel, Complex karyotypes in a series of pediatric osteosarcomas, Cancer Genet Cytogenet 38 (1989), 89-100.
68. F. Mertens, N. Mandahl, C. Orndal, B. Baldetorp, H. C. Bauer, A. Rydholm et al. , Cytogenetic findings in 33 osteosarcomas, Int J Cancer 55 (1993), 44-50.
69. J. A. Fletcher, M. C. Gebhardt and H. P. Kozakewich, Cytogenetic aberrations in osteosarcomas. Nonrandom deletions, rings, and double-minute chromosomes, Cancer Genet Cytogenet 77 (1994), 81-88.
70. J. A. Bridge, M. Nelson, E. McComb, M. H. McGuire, H. Rosenthal, G. Vergara et al. , Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature, Cancer Genet Cytogenet 95 (1997), 74-87.
71. A. A. Sandberg and J. A. Bridge, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors, Cancer Genet Cytogenet 145 (2003), 1-30.
72. M. Tarkkanen, T. Bohling, G. Gamberi, P. Ragazzini, M. S. Benassi, A. Kivioja et al. , Comparative genomic hybridization of low-grade central osteosarcoma, Mod Pathol 11 (1998), 421-426.
73. M. Zielenska, P. Marrano, P. Thorner, J. Pei, B. Beheshti, M. Ho et al. , High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalinfixed paraffin-embedded tissue, Cytogenet Genome Res 107 (2004), 77-82.
74. L. Sangiorgi, G. A. Gobbi, E. Lucarelli, S. M. Sartorio, M. Mordenti, I. Ghedini et al. , Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness, Int J Cancer 95 (2001), 156-161.
75. G. A. Ulaner, H. Y. Huang, J. Otero, Z. Zhao, L. Ben-Porat, J. M. Satagopan et al. , Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma, Cancer Res 63 (2003), 1759-1763.
76. G. R. J. Reifenberger, K. Ichimura, P. S. Meltzer and V. P. Collins, Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2, Cancer Res 54 (1994), 4299-4303.
77. M. Tarkkanen, I. Elomaa, C. Blomqvist, A. H. Kivioja, P. Kellokumpu-Lehtinen, T. Bohling et al. , DNAsequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma, Int J Cancer 84 (1999), 114-121.
78. M. F. Hansen, A. Koufos, B. L. Gallie, R. A. Phillips, O. Fodstad, A. Brogger et al. , Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition, Proc Natl Acad Sci U S A 82 (1985), 6216-6220.
79. S. H. Friend, R. Bernards, S. Rogelj, R. A. Weinberg, J. M. Rapaport, D. M. Albert et al. , A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma, Nature 323 (1986), 643-646.
80. J. Toguchida, K. Ishizaki, M. S. Sasaki, M. Ikenaga, M. Sugimoto, Y. Kotoura et al. , Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma, Cancer Res 48 (1988), 3939-3943.
81. M. Ladanyi, R. Lewis, S. C. Jhanwar, W. Gerald, A. G. Huvos and J. H. Healey, MDM2 and CDK4 gene amplification in Ewing's sarcoma, J Pathol 175 (1995), 211-217.
82. P. Ragazzini, G. Gamberi, M. S. Benassi, C. Orlando, R. Sestini, C. Ferrari et al. , Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma, Cancer Detect Prev 23 (1999), 129-136.
83. J. Toguchida, T. Yamaguchi, B. Ritchie, R. L. Beauchamp, S. H. Dayton, G. E. Herrera et al. , Mutation spectrum of the p53 gene in bone and soft tissue sarcomas, Cancer Res 52 (1992), 6194-6199.
84. H. Masuda, C. Miller, H. P. Koeffler, H. Battifora and M. J. Cline, Rearrangement of the p53 gene in human osteogenic sarcomas, Proc Natl Acad Sci U S A 84 (1987), 7716-7719.
85. R. R. Schreck, Tumor suppressor gene (Rb and p53) mutations in osteosarcoma, Pediatr Hematol Oncol 9 (1992), ix- x.
86. M. Overholtzer, P. H. Rao, R. Favis, R. Lu, M. B. Elowitz, F. Barany et al. , The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability, Proc Natl Acad Sci U S A 100 (2003), 11547-11552.
87. J. S. Wunder, N. Gokgoz, R. Parkes, S. B. Bull, S. Eskandarian, A. M. Davis et al. , TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study, J Clin Oncol 23 (2005), 1483-1490.
88. C. W. Miller, A. Aslo, M. J. Campbell, N. Kawamata, B. C. Lampkin and H. P. Koeffler, Alterations of the p15, p16,and p18 genes in osteosarcoma, Cancer Genet Cytogenet 86 (1996), 136-142.
89. K. Obana, H. W. Yang, H. Y. Piao, T. Taki, K. Hashizume, R. Hanada et al. , Aberrations of p16INK4A, p14ARF and p15INK4B genes in pediatric solid tumors, Int J Oncol 23 (2003), 1151-1157.
90. A. Patino-Garcia, E. S. Pineiro, M. Z. Diez, L. G. Iturriagagoitia, F. A. Klussmann and L. S. Ariznabarreta, Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas, J Pediatr Hematol Oncol 25 (2003), 362-367.
91. T. Tsuchiya, K. Sekine, S. Hinohara, T. Namiki, T. Nobori and Y. Kaneko, Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma, Cancer Genet Cytogenet 120 (2000), 91-98.
92. Y. B. Park,M. J. Park, K. Kimura, K. Shimizu, S. H. Lee and J. Yokota, Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines, Cancer Genet Cytogenet 133 (2002), 105-111.
93. A. Maitra, H. Roberts, A. G. Weinberg and J. Geradts, Aberrant expression of tumor suppressor proteins in the Ewing family of tumors, Arch Pathol Lab Med 125 (2001), 1207-1212.
94. G. Gamberi, M. S. Benassi, T. Bohling, P. Ragazzini, L. Molendini, M. R. Sollazzo et al. , C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression, Oncology 55 (1998), 556-563.
95. K. Scotlandi, M. Serra, G. Nicoletti, M. Vaccari, M. C. Manara, G. Nini et al. , Multidrug resistance and malignancy in human osteosarcoma, Cancer Res 56 (1996), 2434-2439.
96. R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey et al. , Expression of HER2/erbB-2 correlates with survival in osteosarcoma, J Clin Oncol 17 (1999), 2781-2788.
97. M. Wolf, W. El-Rifai, M. Tarkkanen, J. Kononen, M. Serra, E. F. Eriksen et al. , Novel findings in gene expression detected in human osteosarcoma by cDNA microarray, Cancer Genet Cytogenet 123 (2000), 128-132.
98. J. A. Squire, J. Pei, P. Marrano, B. Beheshti, J. Bayani, G. Lim et al. , High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use ofCGHanalysis of cDNA microarrays, Genes Chromosomes Cancer 38 (2003), 215-225.
99. T. Nakano, M. Tani, Y. Ishibashi, K. Kimura, Y. B. Park, N. Imaizumi et al. , Biological properties and gene expression associated with metastatic potential of human osteosarcoma, Clin Exp Metastasis 20 (2003), 665-674.
100. K. Rabin, T. K. Man and C. C. Lau, Personalized care of pediatric cancer patients, Nestle Nutr Workshop Ser Pediatr Program 62 (2008), 173-85; discussion 85-88.
101. M. K. Bernstein, H. Paulussen, M. Randall, R. L. Schluck, A. Teot, L. A. Juergens, H. Ewing Sarcoma Family of Tumors, in: Principles and Practice of Pediatric Oncology, D. G. Pizzo PaP, ed. , Philadelphia: Lippincott Williams and Wilkins, 2006, pp. 1002-1032.
102. K. Unni, C. Inwards, J. Bridge, L. Kindblom and L. Wild, Tumors of the bones and joints, Washington: ARP Press; 2005.
103. C. Turc-Carel, I. Philip, M. P. Berger, T. Philip and G. Lenoir, [Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma], C R Seances Acad Sci III 296 (1983), 1101-1103.
104. A. Aurias, C. Rimbaut, D. Buffe, J. M. Zucker and A. Mazabraud, Translocation involving chromosome 22 in Ewing's sarcoma. A cytogenetic study of four fresh tumors, Cancer Genet Cytogenet 12 (1984), 21-25.
105. C. Turc-Carel, I. Philip, M. P. Berger, T. Philip and G. M. Lenoir, Chromosome study of Ewing's sarcoma (ES) cell lines. Consistency of a reciprocal translocation t(11;22) (q24;q12), Cancer Genet Cytogenet 12 (1984), 1-19.
106. J. Whang-Peng, T. J. Triche, T. Knutsen, J. Miser, E. C. Douglass and M. A. Israel, Chromosome translocation in peripheral neuroepithelioma, N Engl J Med 311 (1984), 584-585.
107. P. H. Sorensen, S. L. Lessnick, D. Lopez-Terrada, X. F. Liu, T. J. Triche and C. T. Denny, A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETSfamily transcription factor, ERG, Nat Genet 6 (1994), 146-151.
108. A. A. Sandberg and J. A. Bridge, Updates on cytogenetics and molecular genetics of bone and soft tissue tumors: Ewing sarcoma and peripheral primitive neuroectodermal tumors, Cancer Genet Cytogenet 123 (2000), 1-26.
109. J. Whang-Peng, T. J. Triche, T. Knutsen, J. Miser, S. Kao- Shan, S. Tsai et al. , Cytogenetic characterization of selected small round cell tumors of childhood, Cancer Genet Cytogenet 21 (1986), 185-208.
110. O. Delattre, J. Zucman, B. Plougastel, C. Desmaze, T. Melot, M. Peter et al. , Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours, Nature 359 (1992), 162-165.
111. J. Zucman, O. Delattre, C. Desmaze, B. Plougastel, I. Joubert, T. Melot et al. , Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints, Genes Chromosomes Cancer 5 (1992), 71-277.
112. W. A. May, M. L. Gishizky, S. L. Lessnick, L. B. Lunsford, B. C. Lewis, O. Delattre et al. , Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation, Proc Natl Acad Sci U S A 90 (1993), 5752-5756.
113. J. Zucman, T. Melot, C. Desmaze, J. Ghysdael, B. Plougastel, M. Peter et al. , Combinatorial generation of variable fusion proteins in the Ewing family of tumours, Embo J 12 (1993), 4481-4487.
114. I. S. Jeon, J. N. Davis, B. S. Braun, J. E. Sublett, M. F. Roussel, C. T. Denny et al. , A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1, Oncogene 10 (1995), 1229-1234.
115. T. L. Ng, M. J. O'Sullivan, C. J. Pallen, M. Hayes, P. W. Clarkson, M. Winstanley et al. , Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV, J Mol Diagn 9 (2007), 459-463.
116. M. Peter, J. Couturier, H. Pacquement, J. Michon, G. Thomas, H. Magdelenat et al. , A new member of the ETS family fused to EWS in Ewing tumors, Oncogene 14 (1997), 1159-1164.
117. L. Wang, R. Bhargava, T. Zheng, L. Wexler, M. H. Collins, D. Roulston et al. , Undifferentiated small round cell sarcomas with rare EWS gene fusions: identification of a novel EWSSP3 fusion and of additional cases with the EWS-ETV1 and EWS-FEV fusions, J Mol Diagn 9 (2007), 498-509.
118. W. A. May, A. Arvand, A. D. Thompson, B. S. Braun, M. Wright and C. T. Denny, EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic, Nat Genet 17 (1997), 495-497.
119. K. L. Rossow and R. Janknecht, The Ewing's sarcoma gene product functions as a transcriptional activator, Cancer Res 61 (2001), 2690-2695.
120. A. Arvand and C. T. Denny, Biology of EWS/ETS fusions in Ewing's family tumors, Oncogene 20 (2001), 5747-5754.
121. S. L. Lessnick, C. S. Dacwag and T. R. Golub, The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts, Cancer Cell 1 (2002), 393-401.
122. B. Deneen, S. M. Welford, T. Ho, F. Hernandez, I. Kurland and C. T. Denny, PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins, Mol Cell Biol 23 (2003), 3897-3908.
123. A. Takahashi, F. Higashino, M. Aoyagi, K. Yoshida, M. Itoh, S. Kyo et al. , EWS/ETS fusions activate telomerase in Ewing's tumors, Cancer Res 63 (2003), 8338-8344.
124. A. Uren, V. Wolf, Y. F. Sun, A. Azari, J. S. Rubin and J. A. Toretsky, Wnt/Frizzled signaling in Ewing sarcoma, Pediatr Blood Cancer 43 (2004), 243-249.
125. H. Y. Huang, P. B. Illei, Z. Zhao, M. Mazumdar, A. G. Huvos, J. H. Healey et al. , Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse, J Clin Oncol 23 (2005), 548-558.
126. M. S. Staege, C. Hutter, I. Neumann, S. Foja, U. E. Hattenhorst, G. Hansen et al. , DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets, Cancer Res 64 (2004), 8213-8221.
127. D. H. Wai, K. L. Schaefer, A. Schramm, E. Korsching, F. Van Valen, T. Ozaki et al. , Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays, Int J Oncol 20 (2002), 441-451.
128. A. Ohali, S. Avigad, R. Zaizov, R. Ophir, S. Horn-Saban, I. J. Cohen et al. , Prediction of high risk Ewing's sarcoma by gene expression profiling, Oncogene 23 (2004), 8997-9006.
129. H. Komuro, Y. Hayashi, M. Kawamura, K. Hayashi, Y. Kaneko, S. Kamoshita et al. , Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas, Cancer Res 53 (1993), 5284-5288.
130. R. Hamelin, J. Zucman, T. Melot, O. Delattre and G. Thomas, p53 mutations in human tumors with chimeric EWS/FLI-1 genes, Int J Cancer 57 (1994), 336-340.
131. S. Mousses, L. McAuley, R. S. Bell, R. Kandel and I. L. Andrulis, Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas, Mod Pathol 9 (1996), 1-6.
132. A. Pellin, J. Boix-Ferrero, D. Carpio, D. Lopez-Terrada, C. Carda, S. Navarro et al. , Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas, Diagn Mol Pathol 6 (1997), 333-341.
133. J. Zhang, S. Hu, D. E. Schofield, P. H. Sorensen and T. J. Triche, Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas, Cancer Res 64 (2004), 6026-6034.
134. P. H. Sorensen, X. F. Liu, O. Delattre, J. M. Rowland, C. A. Biggs, G. Thomas et al. , Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood, Diagn Mol Pathol 2 (1993), 147-157.
135. B. Dockhorn-Dworniczak, K. L. Schafer, R. Dantcheva, S. Blasius, F. van Valen, S. Burdach et al. , [Detection of EWS- /FLI-1 gene fusion transcripts by RT-PCR as a tool in the diagnosis of tumors of the Ewing sarcoma group], Verh Dtsch Ges Pathol 78 (1994), 214-219.
136. F. G. Barr, Q. B. Xiong and K. Kelly, A consensus polymerase chain reaction-oligonucleotide hybridization approach for the detection of chromosomal translocations in pediatric bone and soft tissue sarcomas, Am J Clin Pathol 104 (1995), 627-633.
137. D. A. Hill, M. J. O'Sullivan, X. Zhu, R. T. Vollmer, P. A. Humphrey, L. P. Dehner et al. , Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a rospective study, Am J Surg Pathol 26 (2002), 965-977.
138. R. S. Bridge, V. Rajaram, L. P. Dehner, J. D. Pfeifer and J. D. Perry, Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors, Mod Pathol 19 (2006), 1-8.
139. C. Desmaze, J. Zucman, O. Delattre, T. Melot, G. Thomas and A. Aurias, Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes, Cancer Genet Cytogenet 74 (1994), 13-18.
140. S. Kumar, S. Pack, D. Kumar, R. Walker, M. Quezado, Z. Zhuang et al. , Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffinembedded tissue, Hum Pathol 30 (1999), 324-330.
141. H. Monforte-Munoz, D. Lopez-Terrada, H. Affendie, J. M. Rowland and T. J. Triche, Documentation of EWS gene rearrangements by fluorescence in-situ hybridization (FISH) in frozen sections of Ewing's sarcoma-peripheral primitive neuroectodermal tumor, Am J Surg Pathol 23 (1999), 309-315.
142. M. Peter, H. Magdelenat, J. Michon, T. Melot, O. Oberlin, J. M. Zucker et al. , Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction, Br J Cancer 72 (1995), 96-100.
143. J. A. Toretsky, L. Neckers and L. H. Wexler, Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of patients with Ewing's sarcoma family of tumors, J Natl Cancer Inst 87 (1995), 385-386.
144. E. de Alava, M. D. Lozano, A. Patino, L. Sierrasesumaga and F. J. Pardo-Mindan, Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection ofminimal residual disease in peripheral blood samples, Diagn Mol Pathol 7 (1998), 152-157.
145. A. Zoubek, H. Kovar, M. Kronberger, G. Amann, R. Windhager, B. Gruber et al. , Mobilization of tumour cells during biopsy in an infant with Ewing sarcoma, Eur J Pediatr 155 (1996), 373-376.
146. S. Avigad, I. J. Cohen, J. Zilberstein, E. Liberzon, Y. Goshen, S. Ash et al. , The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors, Cancer 100 (2004), 1053-1058.
147. P. P. Lin, R. I. Brody, A. C. Hamelin, J. E. Bradner, J. H. Healey and M. Ladanyi, Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma, Cancer Res 59 (1999), 1428-1432.
148. A. Maksimenko, C. Malvy, G. Lambert, J. R. Bertrand, E. Fattal, J. Maccario et al. , Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies, Pharm Res 20 (2003), 1565-1567.
149. H. A. Chansky, F. Barahmand-Pour, Q. Mei, W. Kahn- Farooqi, A. Zielinska-Kwiatkowska, M. Blackburn et al. , Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro, J Orthop Res 22 (2004), 910-917.
150. M. Hede, RNA-based nanoparticle treatment shows promise in Ewing's sarcoma model, J Natl Cancer Inst 97 (2005), 627.
151. H. Guan, Z. Zhou, H. Wang, S. F. Jia,W. Liu and E. S. Kleinerman, A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model, Clin Cancer Res 11 (2005), 2662-2669.
152. M. Hidalgo and E. K. Rowinsky, The rapamycin-sensitive signal transduction pathway as a target for cancer therapy, Oncogene 19 (2000), 6680-6686.
153. R. Longtin, Ewing's sarcoma: a miracle drug waiting to happen? J Natl Cancer Inst 95 (2003), 1574-1576.
154. S. Mateo-Lozano, O. M. Tirado and V. Notario, Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation, Oncogene 22 (2003), 9282-9287.
155. J. S. Dome, E. J. Perlman,M. L. Ritchey, M. J. Coppes, J. Karapurakal and P. E. Grundy, Renal Tumors, in: Principles and Practice of Pediatric Oncology, P. A. Pizzo andD. G. Poplack, eds, Philadelphia: Lippincott Williams and Wilkins, 2006.
156. M. J. Coppes, D. A. Haber and P. E. Grundy, Genetic events in the development ofWilms' tumor, N Engl JMed 331 (1994), 586-590.
157. L. Yang, Y. Han, F. Suarez Saiz and M. D. Minden, A tumor suppressor and oncogene: the WT1 story, Leukemia 21 (2007), 868-876.
158. D. A. Haber, R. L. Sohn, A. J. Buckler, J. Pelletier, K. M. Call and D. E. Housman, Alternative splicing and genomic structure of the Wilms tumor gene WT1, Proc Natl Acad Sci U S A 88 (1991), 9618-9622.
159. K. M. Call, T. Glaser, C. Y. Ito, A. J. Buckler, J. Pelletier, D. A. Haber et al. , Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11Wilms' tumor locus, Cell 60 (1990), 509-520.
160. K. Horiuchi, M. Umetani, T. Minami, H. Okayama, S. Takada, M. Yamamoto et al. , Wilms' tumor 1-associating protein regulates G2/M transition through stabilization of cyclin A2 mRNA, Proc Natl Acad Sci U S A 103 (2006), 17278-17283.
161. A. K. Charles, K. W. Brown and P. J. Berry, Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development, Am J Pathol 153 (1998), 991-1000.
162. M. J. Coppes, G. J. Liefers, P. Paul, H. Yeger and B. R. Williams, Homozygous somaticWt1 point mutations in sporadic unilateral Wilms tumor, Proc Natl Acad Sci U S A 90 (1993), 1416-1419.
163. A. E. Reeve, S. A. Sih, A. M. Raizis and A. P. Feinberg, Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells, Mol Cell Biol 9 (1989), 1799-1803.
164. M. Steenman, A. Westerveld and A. Mannens, Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways, Genes Chromosomes Cancer 28 (2000), 1-13.
165. E. R. Maher and W. Reik, Beckwith-Wiedemann syndrome: imprinting in clusters revisited, J Clin Invest 105 (2000), 247-252.
166. M. N. Rivera, W. J. Kim, J. Wells, D. R. Driscoll, B. W. Brannigan, M. Han et al. , An X chromosome gene, WTX, is commonly inactivated in Wilms tumor, Science 315 (2007), 642-645.
167. M. B. Major, N. D. Camp, J. D. Berndt, X. Yi, S. J. Goldenberg, C. Hubbert et al. , Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling, Science 316 (2007), 1043-1046.
168. P. E. Grundy, N. E. Breslow, S. Li, E. Perlman, J. B. Beckwith, M. L. Ritchey et al. , Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorablehistology Wilms tumor: a report from the National Wilms Tumor Study Group, J Clin Oncol 23 (2005), 7312-7321.
169. P. Grundy, Molecular basis of Wilms' tumor, Cancer Treat Res 92 (1997), 101-123.
170. D. Perotti, M. A. Testi, P. Mondini, S. Pilotti, E. D. Green, A. Pession et al. , Refinement within single yeast artificial chromosome clones of a minimal region commonly deleted on the short arm of chromosome 7 in Wilms tumours, Genes Chromosomes Cancer 31 (2001), 42-47.
171. A. J. Beniers, T. Efferth, L. Fuzesi, B. Granzen, R. Mertens and R. Jakse, p53 expression in Wilms' tumor: a possible role as prognostic factor, Int J Oncol 18 (2001), 133-139.
172. S. Maiti, R. Alam, C. I. Amos and V. Huff, Frequent association of beta-catenin and WT1 mutations in Wilms tumors, Cancer Res 60 (2000), 6288-6292.
173. C. Jones, M. Rodriguez-Pinilla, M. Lambros, D. Bax, B. Messahel, G. M. Vujanic et al. , c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours, J Clin Pathol 60 (2007), 1226-1231.
174. J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey et al. , High telomerase reverse transcriptase (hTERT)messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor, Cancer Res 59 (1999), 4301-4307.
175. A. Eggert, M. A. Grotzer, N. Ikegaki, H. Zhao, A. Cnaan, G. M. Brodeur et al. , Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor, J Clin Oncol 19 (2001), 689-696.
176. S. Takamizawa, D. Scott, J. Wen, P. Grundy, W. Bishop, K. Kimura et al. , The survivin:fas ratio in pediatric renal tumors, J Pediatr Surg 36 (2001), 37-42.
177. M. Y. Arcellana-Panlilio, R. M. Egeler, E. Ujack, A. Pinto, D. J. Demetrick, S. M. Robbins et al. , Decreased expression of the INK4 family of cyclin-dependent kinase inhibitors in Wilms tumor, Genes Chromosomes Cancer 29 (2000), 63-69.
178. Y. Stewenius, Y. Jin, I. Ora, J. de Kraker, J. Bras, A. Frigyesi et al. , Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors, Clin Cancer Res 13 (2007), 6593-6602.
179. E. C. Ruteshouser and V. Huff, Familial Wilms tumor, Am J Med Genet C Semin Med Genet 129C (2004), 29-34.
180. N. Rahman, F. Abidi, D. Ford, L. Arbour, E. Rapley, P. Tonin et al. , Confirmation of FWT1 as a Wilms' tumour susceptibility gene and phenotypic characteristics of Wilms' tumour attributable to FWT1, Hum Genet 103 (1998), 547-556.
181. J. M. McDonald, E. C. Douglass, R. Fisher, C. F. Geiser, C. E. Krill, L. C. Strong et al. , Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors, Cancer Res 58 (1998), 1387-1390.
182. R. A. Altura, M. Valentine, H. Li, J. M. Boyett, P. Shearer, P. Grundy et al. , Identification of novel regions of deletion in familial Wilms' tumor by comparative genomic hybridization, Cancer Res 56 (1996), 3837-3841.
183. R. H. Scott, C. A. Stiller, L. Walker and N. Rahman, Syndromes and constitutional chromosomal abnormalities associated withWilms tumour, JMedGenet 43 (2006), 705-715.
184. U. Francke, L. B. Holmes, L. Atkins and V. M. Riccardi, Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13, Cytogenet Cell Genet 24 (1979), 185-192.
185. P. N. Baird, A. Santos, N. Groves, L. Jadresic and J. K. Cowell, Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome, Hum Mol Genet 1 (1992), 301-305.
186. M. J. Coppes, G. J. Liefers, M. Higuchi, A. B. Zinn, J. W. Balfe and B. R. Williams, Inherited WT1 mutation in Denys-Drash syndrome, Cancer Res 52 (1992), 6125-6128.
187. M. H. Little, K. A. Williamson, M. Mannens, A. Kelsey, C. Gosden, N. D. Hastie et al. , Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominantnegative fashion, Hum Mol Genet 2 (1993), 259-264.
188. P. Argani and P. Ladanyi, Translocation carcinomas of the kidney, Clin Lab Med 25 (2005), 363-378.
189. P. Argani, C. R. Antonescu, P. B. Illei, M. Y. Lui, C. F. Timmons, R. Newbury et al. , Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents, Am J Pathol 159 (2001), 179-192.
190. E. Zambrano and M. Reyes-Mugica, Renal cell carcinoma with t(X;17): singular pediatric neoplasm with specific phenotype/ genotype features, Pediatr Dev Pathol 6 (2003), 84-87.
191. C. Perot, L. Boccon-Gibod, R. Bouvier, F. Doz, J. C. Fournet, P. Freneaux et al. , Five new cases of juvenile renal cell carcinoma with translocations involving Xp11. 2: a cytogenetic andmorphologic study, Cancer Genet Cytogenet 143 (2003), 93-99.
192. E. Bruder, O. Passera, D. Harms, I. Leuschner, M. Ladanyi, P. Argani et al. , Morphologic and molecular characterization of renal cell carcinoma in children and young adults, Am J Surg Pathol 28 (2004), 1117-1132.
193. S. K. Sidhar, J. Clark, S. Gill, S. Hamoudi, A. J. Crew, R. Gwilliam et al. , The t(X;1)(p11. 2;q21. 2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene, Hum Mol Genet 5 (1996), 1333-1338.
194. M. A. Weterman, M. Wilbrink and A. Geurts van Kessel, Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)- positive papillary renal cell carcinomas, Proc Natl Acad Sci U S A 93 (1996), 15294-15298.
195. P. Argani, A. Hawkins, C. A. Griffin, J. D. Goldstein, M. Haas, J. B. Beckwith et al. , A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21. 1;q12) chromosome translocation, Am J Pathol 158 (2001), 2089-2096.
196. P. Argani, M. Lae, B. Hutchinson, V. E. Reuter, M. H. Collins, J. Perentesis et al. , Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR, Am J Surg Pathol 29 (2005), 230-240.
197. J. Anderson, S. Gibson andN. J. Sebire, Expression of ETV6- NTRK in classical, cellular andmixed subtypes of congenital mesoblastic nephroma, Histopathology 48 (2006), 748-753.
198. S. R. Knezevich, M. J. Garnett, T. J. Pysher, J. B. Beckwith, P. E. Grundy and P. H. Sorensen, ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma, Cancer Res 58 (1998), 5046-5048.
199. I. Versteege, N. Sevenet, J. Lange, M. F. Rousseau-Merck, P. Ambros, R. Handgretinger et al. , Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer, Nature 394 (1998), 203-206.
200. P. C. Burger, I. T. Yu, T. Tihan, H. S. Friedman, D. R. Strother, J. L. Kepner et al. , Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancyand childhood requently mistaken for medulloblastoma: a PediatricOncology Group study, AmJ Surg Pathol 22 (1998), 1083-1092.
201. R. J. Sinke, R. F. Suijkerbuijk, B. de Jong, J. W. Oosterhuis and A. Geurts van Kessel, Uniparental origin of i(12p) in human germ cell tumors, Genes Chromosomes Cancer 6 (1993), 161-165.
202. E. Rodriguez, J. Houldsworth, V. E. Reuter, P. Meltzer, J. Zhang, J. M. Trent et al. , Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors, Genes Chromosomes Cancer 8 (1993), 230-236.
203. L. H. Looijenga, A. J. Gillis, W. L. Van Putten and J. W. Oosterhuis, In situ numeric analysis of centromeric regions of chromosomes 1, 12, and 15 of seminomas, nonseminomatous germ cell tumors, and carcinoma in situ of human testis, Lab Invest 68 (1993), 211-219.
204. W. M. Korn, D. E. Oide Weghuis, R. F. Suijkerbuijk, U. Schmidt, T. Otto, S. du Manoir et al. , Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization, Genes Chromosomes Cancer 17 (1996), 78-87.
205. S. Mathew, V. V. Murty, G. J. Bosl and R. S. Chaganti, Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors, Cancer Res 54 (1994), 6265-6269.
206. S. Ganguly, V. V. Murty, F. Samaniego, V. E. Reuter, G. J. Bosl andR. S. Chaganti, Detection of preferentialNRASmutations in human male germ cell tumors by the polymerase chain reaction, Genes Chromosomes Cancer 1 (1990), 228-232.
207. T. Shuin, H. Misaki, Y. Kubota, M. Yao and M. Hosaka, Differential expression of protooncogenes in human germ cell tumors of the testis, Cancer 73 (1994), 1721-1727.
208. R. A. Lothe, N. Hastie, K. Heimdal, S. D. Fossa, A. E. Stenwig and A. L. Borresen, Frequent loss of 11p13 and 11p15 loci in male germ cell tumours, Genes Chromosomes Cancer 7 (1993), 96-101.
209. V. V. Murty, R. G. Li, J. Houldsworth, D. L. Bronson, V. E. Reuter, G. J. Bosl et al. , Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors, Oncogene 9 (1994), 3227-3231.
210. A. De Backer, G. C. Madern, J. W. Oosterhuis, F. G. Hakvoort- Cammel and F. W. Hazebroek, Ovarian germ cell tumors in children: a clinical study of 66 patients, Pediatr Blood Cancer 46 (2006), 459-464.
211. U. Surti, L. Hoffner, A. Chakravarti and R. E. Ferrell, Genetics and biology of human ovarian teratomas. I. Cytogenetic analysis and mechanism of origin, Am J Hum Genet 47 (1990), 635-643.
212. M. A. Riopel, A. Spellerberg, C. A. Griffin and E. J. Perlman, Genetic analysis of ovarian germ cell tumors by comparative genomic hybridization, Cancer Res 58 (1998), 3105-3110.
213. D. T. Schneider, A. E. Schuster, M. K. Fritsch, G. Calaminus, U. Gobel, D. Harms et al. , Genetic analysis of mediastinal nonseminomatous germ cell tumors in children and adolescents, Genes Chromosomes Cancer 34 (2002), 115-125.
214. M. Ladanyi, F. Samaniego, V. E. Reuter, R. J. Motzer, S. C. Jhanwar, G. J. Bosl et al. , Cytogenetic and immunohistochemical evidence for the germcell origin of a subset of acute leukemias associated with mediastinal germ cell tumors, J Natl Cancer Inst 82 (1990), 221-227.
215. I. T. Yu, C. A. Griffin, P. C. Phillips, L. C. Strauss and E. J. Perlman, Numerical sex chromosomal abnormalities in pineal teratomas by cytogenetic analysis and fluorescence in situ hybridization, Lab Invest 72 (1995), 419-423.
216. K. J. Bussey, H. J. Lawce, S. B. Olson, D. C. Arthur, D. K. Kalousek, M. Krailo et al. , Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences - a Children's Cancer Group study, Genes Chromosomes Cancer 25 (1999), 134-146.
217. E. J. Perlman, B. Cushing, E. Hawkins and C. A. Griffin, Cytogenetic analysis of childhood endodermal sinus tumors: a Pediatric Oncology Group study, Pediatr Pathol 14 (1994), 695-708.
218. E. J. Perlman, J. Hu, D. Ho, B. Cushing, S. Lauer and R. P. Castleberry, Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization, J Pediatr Hematol Oncol 22 (2000), 100-105.
219. E. B. Hook and D. Warburton, The distribution of chromosomal genotypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism, Hum Genet 64 (1983), 24-27.
220. Y. F. Lau, Gonadoblastoma, testicular and prostate cancers, and the TSPY gene, Am J Hum Genet 64 (1999), 921-927.
221. C. R. Nichols, N. A. Heerema, C. Palmer, P. J. Sr. Loehrer, S. D. Williams and L. H. Einhorn, Klinefelter's syndrome associated with mediastinal germ cell neoplasms, J Clin Oncol 5 (1987), 1290-1294.
222. S. Sievers, K. Alemazkour, S. Zahn, E. J. Perlman, A. J. Gillis, L. H. Looijenga et al. , IGF2/H19 imprinting analysis of human germ cell tumors (GCTs) using the methylationsensitive single-nucleotide primer extension method reflects the origin of GCTs in different stages of primordial germ cell development, Genes Chromosomes Cancer 44 (2005), 256-264.
223. S. Furukawa, M. Haruta, Y. Arai, S. Honda, J. Ohshima, W. Sugawara et al. , Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes, Cancer Sci 100 (2009), 698-708.
224. J. M. Dunn, R. A. Phillips, A. J. Becker and B. L. Gallie, Identification of germline and somatic mutations affecting the retinoblastoma gene, Science 241 (1988), 1797-1800.
225. A. G. Jr. Knudson, Mutation and cancer: statistical study of retinoblastoma, Proc Natl Acad Sci U S A 68 (1971), 820-823.
226. D. R. Lohmann and B. L. Gallie, Retinoblastoma: revisiting the model prototype of inherited cancer, Am J Med Genet C Semin Med Genet 129C (2004), 23-28.
227. T. P. Dryja, S. Mukai, R. Petersen, J. M. Rapaport, D. Walton and D. W. Yandell, Parental origin of mutations of the retinoblastoma gene, Nature 339 (1989), 556-558.
228. X. P. Zhu, J. M. Dunn, R. A. Phillips, A. D. Goddard, K. E. Paton, A. Becker et al. , Preferential germline mutation of the paternal allele in retinoblastoma, Nature 340 (1989), 312-313.
229. J. W. Harbour and D. C. Dean, Rb function in cell-cycle regulation and apoptosis, Nat Cell Biol 2 (2000), E65-67.
230. J. Schappert-Kimmijser, G. D. Hemmes and R. Nijland, The heredity of retinoblastoma, Ophthalmologica 151 (1966), 197-213.
231. B. Strahm and D. Malkin, Hereditary cancer predisposition in children: genetic basis and clinical implications, Int J Cancer 119 (2006), 2001-2006.
232. O. Fletcher, D. Easton, K. Anderson, C. Gilham, M. Jay and M. Peto, Lifetime risks of common cancers amongretinoblastoma survivors, J Natl Cancer Inst 96 (2004), 357-363.
233. W. H. Lee, R. Bookstein, F. Hong, L. J. Young, J. Y. Shew and E. Y. Lee, Human retinoblastoma susceptibility gene: cloning, identification, and sequence, Science 235 (1987), 1394-1399.
234. M. Classon and E. Harlow, The retinoblastoma tumour suppressor in development and cancer, Nat Rev Cancer 2 (2002), 910-917.
235. J. W. Harbour, Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening, Ophthalmology 105 (1998), 1442-1447.
236. C. Stirzaker, D. S. Millar, C. L. Paul, P. M. Warnecke, J. Harrison, P. C. Vincent et al. , Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors, Cancer Res 57 (1997), 2229-2237.
237. K. Priya, S. R. Jada, B. L. Quah, T. C. Quah and P. S. Lai, High incidence of allelic loss at 16q12. 2 region spanning RBL2/p130 gene in retinoblastoma, Cancer Biol Ther 8 (2009), 714-717.
238. S. Chakraborty, S. Khare, S. K. Dorairaj, V. C. Prabhakaran, D. R. Prakash and D. R. Kumar, Identification of genes associated with tumorigenesis of retinoblastoma by microarray analysis, Genomics 90 (2007), 344-353.
239. BL-T, D. Mueller and M. J. Finegold, Tumors of the liver, in: Principles and Practice of Pediatric Oncology, (5th ed. ), D. G. Poplack PAPa, ed. , Philadelphia: Lippincott Williams and Wilkins; 2006, pp. 887-904.
240. A. Darbari, K. M. Sabin, C. N. Shapiro and K. B. Schwarz, Epidemiology of primary hepatic malignancies in U. S. children, Hepatology 38 (2003), 560-566.
241. A. G. Weinberg and M. J. Finegold, Primary hepatic tumors of childhood, Hum Pathol 14 (1983), 512-537.
242. F. F. Bellani and M. Massimino, Liver tumors in childhood: epidemiology and clinics, J Surg Oncol Suppl 3 (1993), 119-121.
243. R. L. Meyers, J. R. Rowland, M. Krailo, Z. Chen, H. M. Katzenstein and M. H. Malogolowkin, Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children's Oncology Group, Pediatr Blood Cancer 53 (2009), 1016-1022.
244. G. E. Tomlinson, E. C. Douglass, B. H. Pollock, M. J. Finegold and N. R. Schneider, Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21, Genes Chromosomes Cancer 44 (2005), 177-184.
245. R. G. Weber, T. Pietsch, D. von Schweinitz and D. Lichter, Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome, Am J Pathol 157 (2000), 571-578.
246. M. Mullarkey, C. J. Breen, M. McDermott, A. O'Meara and R. L. Stallings, Genetic abnormalities in a pre and postchemotherapy hepatoblastoma, Cytogenet Cell Genet 95 (2001), 9-11.
247. J. A. Fletcher, H. P. Kozakewich, K. Pavelka, H. E. Grier, R. C. Shamberger, B. Korf et al. , Consistent cytogenetic aberrations in hepatoblastoma: a common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies? Genes Chromosomes Cancer 3 (1991), 37-43.
248. E. Rodriguez, V. E. Reuter, C. Mies, G. J. Bosl and R. S. Chaganti, Abnormalities of 2q: a common genetic link between rhabdomyosarcoma and hepatoblastoma? Genes Chromosomes Cancer 3 (1991), 122-127.
249. A. Koufos,M. F. Hansen, N. G. Copeland, N. A. Jenkins, B. C. Lampkin and W. K. Cavenee, Loss of heterozygosity in threeembryonal tumours suggests a common pathogenetic mechanism, Nature 316 (1985), 330-334.
250. I. Hatada, H. Ohashi, Y. Fukushima, Y. Kaneko, M. Inoue, Y. Komoto et al. , An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome, Nat Genet 14 (1996), 171-173.
251. D. O'Keefe, D. Dao, L. Zhao, R. Sanderson, D. Warburton, L. Weiss et al. , Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors, Am J Hum Genet 61 (1997), 295-303.
252. M. P. Lee, M. DeBaun, G. Randhawa, B. A. Reichard, S. J. Elledge and A. P. Feinberg, Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome, Am J Hum Genet 61 (1997), 304-309.
253. C. M. Lam, S. T. Fan, C. M. Lo and J. Wong, Major hepatectomy for hepatocellular carcinoma in patients with an unsatisfactory indocyanine green clearance test, Br J Surg 86 (1999), 1012-1017.
254. W. Hartmann, A. Waha, A. Koch, C. G. Goodyer, S. Albrecht, D. von Schweinitz et al. , p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19, Am J Pathol 157 (2000), 1393-1403.
255. S. Albrecht, D. von Schweinitz, A. Waha, J. A. Kraus, A. von Deimling and T. Pietsch, Loss of maternal alleles on chromosome arm 11p in hepatoblastoma, Cancer Res 54 (1994), 5041-5044.
256. T. Eriksson, T. Frisk, S. G. Gray, D. von Schweinitz, T. Pietsch, C. Larsson et al. , Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma, Exp Cell Res 270 (2001), 88-95.
257. J. A. Toretsky, N. L. Zitomersky, A. E. Eskenazi, R. W. Voigt, E. D. Strauch, C. C. Sun et al. , Glypican-3 expression in Wilms tumor and hepatoblastoma, J Pediatr Hematol Oncol 23 (2001), 496-499.
258. H. von Horn, M. Tally, K. Hall, T. Eriksson, T. J. Ekstrom and S. G. Gray, Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas, Cancer Lett 162 (2001), 253-260.
259. H. Kim, E. K. Ham, Y. I. Kim, J. G. Chi, H. S. Lee, S. H. Park et al. , Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas, Cancer Lett 131 (1998), 177-183.
260. A. Iolascon, L. Giordani, A. Moretti, G. Basso, G. Borriello and F. Della Ragione, Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma, Hepatology 27 (1998), 989-995.
261. S. Pakakasama, T. T. Chen, W. Frawley, C. Y. Muller, E. C. Douglass, E. C. Lee et al. , CCND1 polymorphism and age of onset of hepatoblastoma, Oncogene 23 (2004), 4789-4792.
262. Y. H. Shim, H. J. Park, M. S. Choi, J. S. Kim, H. Kim, J. J. Kim et al. , Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma, Mod Pathol 16 (2003), 430-436.
263. M. Brotto and M. J. Finegold, Distinct patterns of p27/KIP 1 gene expression in hepatoblastoma and prognostic implications with correlation before and after chemotherapy, Hum Pathol 33 (2002), 198-205.
264. A. Kiss, A. Szepesi, G. Lotz, P. Nagy and P. Schaff, Expression of transforming growth factor-alpha in hepatoblastoma, Cancer 83 (1998), 690-697.
265. E. Hiyama, H. Yamaoka, T. Matsunaga, Y. Hayashi, H. Ando, S. Suita et al. , High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma, Br J Cancer 91 (2004), 972-979.
266. C. Armengol, S. Cairo,M. Fabre andM. A. Buendia,Wnt signaling and hepatocarcinogenesis: The hepatoblastoma model, Int J Biochem Cell Biol, 2009.
267. H. Takayasu, H. Horie, E. Hiyama, T. Matsunaga, Y. Hayashi, Y. Watanabe et al. , Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma, Clin Cancer Res 7 (2001), 901-908.
268. W. S. Park, R. R. Oh, J. Y. Park, P. J. Kim, M. S. Shin, J. H. Lee et al. , Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma, J Pathol 193 (2001), 483-490.
269. D. Lopez-Terrada, P. H. Gunaratne, A. M. Adesina, J. Pulliam, D. M. Hoang, Y. Nguyen et al. , Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt andNotch pathway activation inDLK+ precursors, Hum Pathol 40 (2009), 783-794.
270. H. Oda, Y. Imai, Y. Nakatsuru, J. Hata and J. Ishikawa, Somatic mutations of the APC gene in sporadic hepatoblastomas, Cancer Res 56 (1996), 3320-3323.
271. K. Taniguchi, L. R. Roberts, I. N. Aderca, X. Dong, C. Qian, L. M. Murphy et al. , Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas, Oncogene 21 (2002), 4863-4871.
272. A. Koch, A. Waha, W. Hartmann, A. Hrychyk, U. Schuller, U. Waha et al. , Elevated expression of Wnt antagonists is a common event in hepatoblastomas, Clin Cancer Res 11 (2005), 4295-4304.
273. S. Cairo, C. Armengol, A. De Reynies, Y. Wei, E. Thomas, C. A. Renard et al. , Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell 14 (2008), 471-484.